New York, August 14, 2024 - PRISM MarketView - NeuroBo Pharmaceuticals (NRBO) leads the PRISM Biotech Index intraday after a strong Q2 2024 update. The company secured up to $70 million in financing, with $20 million upfront, to fund key milestones through Q2 2025. Highlights include the progress of DA-1726, an obesity treatment showing superior pre-clinical results, with Phase 1 top-line data expected in Q3 2024. Additionally, NeuroBo is advancing DA-1241 for MASH, with Phase 2a results anticipated in Q4 2024.
The company also emphasized its strong financial position to fund key milestones through Q2 2025.
“During the second quarter and subsequently, we made remarkable progress advancing the clinical development of our two next-generation cardiometabolic assets and are now well capitalized to execute on our upcoming DA-1726 milestones following our recent, successful financing of up to $70 million in aggregate gross proceeds, with $20 million upfront and $50 million of clinical milestone-based warrants.”
Hyung Heon Kim, CEO of NeuroBo
About PRISM MarketView:
Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on X.
Disclaimer:
PRISM MarketView is not a registered or licensed broker-dealer or investment adviser and does not offer investment advice. The information provided in this communication is not intended to constitute an offer to sell, a solicitation of an offer to buy, or a recommendation for any security.
Contact:
Prism MarketView | Stock Market News & Investment Opportunities